Genflow hits safety milestone in ageing therapy for dogs

Genflow Biosciences (LSE:GENF) has achieved a key safety milestone for its experimental SIRT6 gene therapy, designed to slow ageing, by successfully administering a second dose to elderly beagles without adverse effects. This continued safety validation strengthens confidence in the company's gene therapy platform, signaling potential for both veterinary and future human applications. The positive results in animal trials present an attractive near-term commercial opportunity in the multi-billion dollar animal health market, with Genflow planning to advance research and explore partnerships.

Analysis

Genflow Biosciences (LSE:GENF) has achieved a significant safety milestone, successfully administering its experimental SIRT6 gene therapy for a second time to a cohort of 28 elderly beagles without adverse effects. This continued safety validation, crucial for a novel gene therapy, underpins the company's platform, which aims to leverage a human centenarian gene to repair DNA and regulate metabolism in aging cells. The ongoing study is slated for completion in January 2026.

This positive safety profile strengthens confidence in Genflow's gene therapy platform, signaling broader potential for both veterinary and future human applications. CEO Dr. Eric Leire highlighted the "attractive near-term commercial opportunity" within the multi-billion dollar animal health market, noting strong engagement from established industry players. This positions animal health as a strategic entry point, complementing the company's core human longevity programs.

With repeat dosing confirmed safe, Genflow intends to advance its animal health research and actively explore partnerships with larger industry participants. As Europe's sole publicly listed longevity business, successful animal trials could establish a new commercial revenue stream while de-risking and validating the technology for eventual human translation.

Key Decisions for Investors

• Investors should assess the implications of validated safety data for Genflow's gene therapy platform, considering its dual potential in veterinary and human longevity markets.
• Evaluate the near-term commercial prospects within the animal health sector, particularly given the stated industry engagement and planned partnerships.
• Monitor the progress of the ongoing beagle study, with results expected in January 2026, as well as any announcements regarding strategic collaborations.